SkinHealth Q2 Sales Miss, But EBITDA Beats; $18M Securities Settlement Booked
SKIN sits 26% above its 52-week low of $0.551 on light trading volume (0.3× avg).
Summary
SkinHealth Systems delivered a mixed Q2: revenue missed but EBITDA beat, while an $18M securities settlement was booked and a reverse split is proposed to address Nasdaq non-compliance.
Key Events · Earnings and Guidance · SKIN
-
Q2 Revenue Miss, EBITDA Beat
Net sales fell 7.8% YoY to $72.1M, missing the $74.3M consensus, while adjusted EBITDA of $17.0M exceeded the $11.6M estimate. Gross margin improved to 68.4% from 62.8% a year ago.
-
$18M Securities Settlement Recorded
The company accrued an $18M liability for the securities class action settlement, with $15M covered by insurance and $3M from its own funds. A corresponding $15M insurance receivable was also recorded.
-
Nasdaq Delisting Risk and Reverse Split Proposal
SkinHealth received a Nasdaq delisting notice for a sub-$1.00 bid price and has proposed a reverse stock split (1-for-5 to 1-for-20) to regain compliance. The stock closed at $0.693 on August 6, 2026.
-
Cash Position and Debt Repayment Plans
Cash and equivalents stood at $206.1M at quarter-end. The company intends to repay the remaining $103.2M of 2026 convertible notes at maturity in Q3 2026 using cash on hand.
Analysis · SKIN · Industrial Applications And Services
A 7.8% drop in revenue to $72.1M—missing consensus—reflects an 18.4% decline in Delivery System sales amid soft macro conditions. Yet adjusted EBITDA of $17M handily topped the $11.6M estimate, thanks to cost cuts and a gross margin surge to 68.4%. The quarter also saw an $18M securities class action settlement recorded, of which only $3M comes from company cash. With $206M in cash and a reverse stock split proposed to cure a Nasdaq delisting notice, the results underscore both operational resilience and lingering legal and listing overhangs.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 34.9% of the 1009 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SKIN was trading at $0.69 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $99.9M. The 52-week trading range was $0.55 to $2.69. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.